Pituitary tumor-transforming protein 1 (PTTG1)

Pituitary tumor-transforming protein 1 (PTTG1), also known as securin, is a multifunctional protein that plays a critical role in maintaining chromosomal stability and regulating the cell cycle [5, 7]. Its primary biological function is to inhibit the protease separase, thereby preventing the premature separation of sister chromatids during mitosis [5, 15]. Beyond its role in the cell cycle, PTTG1 acts as a global transcription factor that modulates the expression of genes involved in cell proliferation, DNA repair, and apoptosis, such as c-Myc and p53 [1, 3, 10]. PTTG1 is recognized as a potent proto-oncogene and is significantly overexpressed in various human malignancies, including pituitary, thyroid, breast, and colorectal cancers [3, 13, 20]. High levels of PTTG1 are frequently associated with increased tumor invasiveness, metastasis, and poor patient prognosis, making it a valuable biomarker for cancer progression [10, 19, 22]. Although no specific PTTG1-targeted drugs are currently FDA-approved, it is an active area of research for experimental therapies like siRNA and antisense oligonucleotides [16, 21]. Additionally, certain small molecules like CDK inhibitors (e.g., PHA-848125) have been shown to indirectly downregulate PTTG1 expression, highlighting its potential as a therapeutic target to induce senescence and apoptosis in cancer cells [7, 12].

Other names

SecurinhPTTGPTTGEAP1TUTR1ECRARTumor-transforming protein 1

PTTG1 is targeted primarily through the inhibition of its expression using RNA interference (siRNA) or antisense oligonucleotides, which leads to reduced cell proliferation, induction of cellular senescence, and increased apoptosis in tumor cells [16, 21]. It can also be indirectly modulated by upstream regulators, such as SIRT1 activators or CDK inhibitors, which decrease PTTG1 protein levels and consequently restore chromosomal stability or sensitize cells to chemotherapy [8, 12].